{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Aarti Drugs Ltd
Aarti Drugs Ltd is Rated Sell
Aarti Drugs Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 01 April 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 24 April 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market standing.
Aarti Drugs Ltd is Rated Sell
Aarti Drugs Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 01 April 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 13 April 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market standing.
Aarti Drugs Ltd Technical Momentum Shifts Amid Mixed Market Signals
Aarti Drugs Ltd has exhibited a subtle shift in its technical momentum, moving from a strongly bearish stance to a mildly bearish trend, reflecting nuanced changes in key indicators such as MACD, RSI, and moving averages. Despite a modest day gain of 1.12%, the pharmaceutical company’s technical landscape remains complex, with mixed signals across weekly and monthly charts suggesting cautious investor sentiment amid broader market challenges.
Aarti Drugs Ltd Gains 6.49%: Two Key Factors Driving the Weekly Rally
Aarti Drugs Ltd delivered a strong weekly performance, rising 6.49% from Rs.330.60 to Rs.352.05 between 30 March and 2 April 2026, significantly outperforming the Sensex which declined 0.29% over the same period. The stock’s rebound was driven by a sharp intraday surge on 1 April and a subsequent upgrade in its investment rating, signalling cautious optimism amid a challenging market backdrop.
Aarti Drugs Ltd Investment Rating Upgraded to Sell on Improving Fundamentals
Aarti Drugs Ltd has seen its investment rating upgraded from Strong Sell to Sell as of 1 April 2026, reflecting a nuanced reassessment of its financial performance, valuation metrics, management efficiency, and technical indicators. Despite ongoing challenges in profitability and operating trends, certain valuation and efficiency parameters have improved, prompting a more balanced outlook for this small-cap pharmaceutical player.
Aarti Drugs Ltd Surges 7.65% to Day's High of Rs 344.2 — Outperforms Sector by 6.28 Percentage Points
The Sensex declined by 2.15% on 1 Apr 2026, yet Aarti Drugs Ltd surged 7.65%, marking a 6.28 percentage-point outperformance over its Pharmaceuticals & Biotechnology sector. This sharp single-session gain rewrites the short-term narrative for the small-cap stock, raising the question of whether this is a genuine recovery or a technical bounce within a broader downtrend.
Aarti Drugs Ltd is Rated Strong Sell
Aarti Drugs Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 25 February 2026. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 31 March 2026, providing investors with the latest insights into the company’s performance and outlook.
Aarti Drugs Ltd is Rated Strong Sell
Aarti Drugs Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 25 February 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 20 March 2026, providing investors with the latest insights into the company’s performance and outlook.
Aarti Drugs Ltd is Rated Strong Sell
Aarti Drugs Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 25 February 2026. However, the analysis and financial metrics presented here reflect the stock’s current position as of 09 March 2026, providing investors with the latest insights into the company’s performance and outlook.
Why is Aarti Drugs Ltd falling/rising?
On 02-Mar, Aarti Drugs Ltd witnessed a notable decline in its share price, closing at ₹357.60, down ₹9.40 or 2.56%. This drop reflects a continuation of recent negative momentum amid broader concerns over the company’s profitability and market performance relative to benchmarks.
Aarti Drugs Ltd Opens with Significant Gap Down Amid Market Concerns
Aarti Drugs Ltd commenced trading today with a pronounced gap down, opening 6.63% lower at Rs 342.65, reflecting heightened market apprehensions following recent developments. The stock’s weak start underscores ongoing pressures within the Pharmaceuticals & Biotechnology sector, as it continues to underperform both its sector peers and the broader market indices.
Aarti Drugs Ltd Falls 1.52%: Technical Shifts and Financial Weakness Define the Week
Aarti Drugs Ltd experienced a challenging week, closing at Rs.367.00 on 27 Feb 2026, down 1.52% from Rs.372.65 the previous Friday. This underperformance was more pronounced than the Sensex’s 0.96% decline over the same period, reflecting a combination of deteriorating technical momentum and weak financial results that weighed on investor sentiment throughout the week.
Aarti Drugs Ltd Downgraded to Strong Sell Amid Weak Financials and Bearish Technicals
Aarti Drugs Ltd has been downgraded from a Sell to a Strong Sell rating as of 25 Feb 2026, reflecting deteriorating technical indicators and disappointing financial performance. The company’s Mojo Score has slipped to 28.0, signalling heightened caution for investors amid a bearish technical outlook, weakening profitability, and subdued valuation metrics despite some operational strengths.
Aarti Drugs Ltd Technical Momentum Shifts Amid Bearish Signals
Aarti Drugs Ltd has experienced a notable shift in its technical momentum, moving from a mildly bearish to a more pronounced bearish trend. Despite a marginal day decline of 0.23%, the stock’s technical indicators, including MACD, RSI, Bollinger Bands, and moving averages, signal increasing downside pressure. This comprehensive analysis explores the evolving technical landscape of Aarti Drugs Ltd, contextualising its performance against broader market benchmarks and sector dynamics.
Aarti Drugs Ltd Upgraded to Sell on Technical Improvement Despite Mixed Financials
Aarti Drugs Ltd has seen its investment rating upgraded from Strong Sell to Sell as of 20 February 2026, reflecting a nuanced shift in its technical outlook and valuation metrics despite ongoing financial challenges. The pharmaceutical company’s Mojo Score has improved to 34.0, signalling a cautious but more optimistic stance amid mixed performance across quality, valuation, financial trends, and technical indicators.
Aarti Drugs Ltd Technical Momentum Shifts Amid Mixed Market Signals
Aarti Drugs Ltd has experienced a subtle shift in its technical momentum, moving from a strongly bearish stance to a mildly bearish trend, reflecting a complex interplay of technical indicators. Despite a modest day gain of 0.22%, the stock’s broader technical signals and relative performance against the Sensex suggest cautious investor sentiment amid ongoing sector challenges.
Aarti Drugs Ltd is Rated Strong Sell
Aarti Drugs Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 04 February 2026. However, the analysis and financial metrics presented here reflect the stock's current position as of 12 February 2026, providing investors with the latest insights into the company’s performance and outlook.
Aarti Drugs Ltd Declines 1.38% Amid Margin Pressures and Valuation Shifts: 4 Key Factors This Week
Aarti Drugs Ltd closed the week ending 6 February 2026 at Rs.375.20, down 1.38% from the previous Friday’s close of Rs.380.45, underperforming the Sensex which gained 1.51% over the same period. The week was marked by significant volatility, including a sharp gap down on 4 February amid margin pressure concerns and a subsequent valuation reassessment. Despite solid year-to-date profit growth, the stock faced operational challenges and bearish technical signals that weighed on investor sentiment.
Has Aarti Drugs Ltd declared dividend?
Yes, Aarti Drugs Ltd has declared a dividend of 20% (₹1 per share) with an ex-date of February 9, 2026. Despite the dividend, the company's stock has experienced significant price declines over various periods, resulting in negative total returns.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
